# A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

> **NCT03742102** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 243 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Capivasertib
- **DRUG:** Oleclumab
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Datopotamab deruxtecan

## Key facts

- **NCT ID:** NCT03742102
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-21
- **Primary completion:** 2024-11-29
- **Final completion:** 2027-02-26
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742102, "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03742102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*